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Summary
Background Comparable data on the global and country-specific burden of neurological disorders and their trends are 
crucial for health-care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors 
(GBD) Study provides such information but does not routinely aggregate results that are of interest to clinicians 
specialising in neurological conditions. In this systematic analysis, we quantified the global disease burden due to 
neurological disorders in 2015 and its relationship with country development level. 
Methods We estimated global and country-specific prevalence, mortality, disability-adjusted life-years (DALYs), years 
of life lost (YLLs), and years lived with disability (YLDs) for various neurological disorders that in the GBD classification 
have been previously spread across multiple disease groupings. The more inclusive grouping of neurological 
disorders included stroke, meningitis, encephalitis, tetanus, Alzheimer’s disease and other dementias, Parkinson’s 
disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, medication overuse 
headache, brain and nervous system cancers, and a residual category of other neurological disorders. We also analysed 
results based on the Socio-demographic Index (SDI), a compound measure of income per capita, education, and 
fertility, to identify patterns associated with development and how countries fare against expected outcomes relative 
to their level of development.
Findings Neurological disorders ranked as the leading cause group of DALYs in 2015 (250·7 [95% uncertainty interval 
(UI) 229·1 to 274·7] million, comprising 10·2% of global DALYs) and the second-leading cause group of deaths (9·4 
[9·1 to 9·7] million], comprising 16·8% of global deaths). The most prevalent neurological disorders were tension-
type headache (1505·9 [UI 1337·3 to 1681·6 million cases]), migraine (958·8 [872·1 to 1055·6] million), medication 
overuse headache (58·5 [50·8 to 67·4 million]), and Alzheimer’s disease and other dementias (46·0 
[40·2 to 52·7 million]). Between 1990 and 2015, the number of deaths from neurological disorders increased by 
36·7%, and the number of DALYs by 7·4%. These increases occurred despite decreases in age-standardised rates of 
death and DALYs of 26·1% and 29·7%, respectively; stroke and communicable neurological disorders were 
responsible for most of these decreases. Communicable neurological disorders were the largest cause of DALYs in 
countries with low SDI. Stroke rates were highest at middle levels of SDI and lowest at the highest SDI. Most of the 
changes in DALY rates of neurological disorders with development were driven by changes in YLLs.
Interpretation Neurological disorders are an important cause of disability and death worldwide. Globally, the burden 
of neurological disorders has increased substantially over the past 25 years because of expanding population numbers 
and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. 
The number of patients who will need care by clinicians with expertise in neurological conditions will continue to 
grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate 
services.
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Introduction
In 2006, WHO emphasised the importance of 
neurological disorders (a group that at the time included 
epilepsy, Alzheimer’s disease and other dementias, 
Parkinson’s disease, multiple sclerosis, migraine, stroke, 
poliomyelitis, tetanus, meningitis, and Japanese 
encephalitis) for public health,1 and estimated that these 
disorders accounted for 6·3% of the global disability-
adjusted life-years (DALYs). However, the WHO report 
was largely based on the Global Burden of Disease Study 
2000 (GBD 2000)2 and did not reflect understanding of 
the comparative global epidemiology of neurological 
disorders. Increasing life expectancy and population 
growth worldwide in recent years mean that more 
people are now reaching ages where neurological 
disorders are most prevalent. Additionally, there have 
been changes in the treatment of some neurological 
disorders (such as the introduction of acute stroke units, 
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thrombolysis, and thrombectomy), as well as changes in 
the risk factors that affect the burden of neurological 
disorders in the world.
To improve health-care planning and health outcomes 
of people with neurological disorders, we must 
understand not only the number and distribution of 
people with these disorders between countries, but also 
how these disorders affect population health (in terms of 
both mortality and disability) compared with other 
diseases and injuries.
The Global Burden of Disease Study 2015 (GBD 2015) 
GBD 20153,4 produced comprehensive and comparable 
estimates of the burden (prevalence, deaths, and DALYs) of 
315 diseases and injuries for 195 countries and territories 
from 1990 to 2015. However, aggregated estimates in the 
category of neurological disorders did not include stroke, 
brain and nervous system cancer, or communicable 
neurological disorders, which are of great relevance to 
neurologists. Ischaemic and haemor rhagic stroke were 
classified as cardiovascular diseases; brain and nervous 
system cancer as malignant neoplasms; and meningitis, 
encephalitis, and tetanus as communicable diseases. In 
this systematic analysis, we quantify the disease burden 
(as measured by prevalence, mortality, DALYs, and years 
lived with disability [YLDs]) due to neurological disorders 
and its relationship with development level as measured 
by the Socio-demographic Index (SDI; an indicator based 
on lagged-distributed income per person, average 
educational attainment among individuals older than 
15 years, and total fertility rate).
Methods
Categorisation of disorders
In an expanded category of neurological disorders we 
included stroke, Alzheimer’s disease and other 
dementias, Parkinson’s disease, epilepsy, multiple 
sclerosis, migraine, tension-type headache, medication 
overuse headache, meningitis, tetanus, encephalitis, 
brain and nervous system cancer, motor neuron disease, 
and a residual category of other neurological disorders 
that included diseases such as muscular dystrophy and 
Huntington’s disease (appendix p 112).
Non-fatal estimates
GBD 2015 non-fatal burden estimates were based on a 
systematic review of the literature to obtain all available 
epidemiological data on prevalence, incidence, risk of 
mortality, and severity. In the appendix we provide for 
each neurological disorder analysed the following: the 
list of International Classification of Diseases (ICD) 
codes used for mapping neurological causes of death (pp 
118–21); a list of GBD sequelae, health states, health state 
lay descriptions, and disability weights for neurological 
disorders (pp 122–39); the total number of site-years by 
neurological cause and source type (p140); and the data 
representativeness index for each neurological disorder, 
the percentage of GBD 2015 geographies with any data 
by cause pertaining to the period before 2005, 2005–15, 
and all years of data (p 141). Reference case definitions 
were based on ICD-9 or ICD-10 criteria with the addition 
of Diagnostic and Statistical Manual of Mental Disorders 
Research in context
Evidence before this study
The Global Burden of Disease Study 2015 (GBD 2015) produced 
comprehensive and comparable estimates of the burden of 
various disorders (prevalence, deaths, and disability-adjusted 
life years [DALYs]) for 195 countries and territories from 1990 
to 2015. However, aggregated estimates in the category of 
neurological disorders did not include data for stroke, brain and 
nervous system cancer, or communicable neurological 
disorders, which are all of great relevance to neurologists. 
Added value of this study
For GBD 2015, the GBD 2013 search strategy was replicated to 
take into account all relevant epidemiological studies published 
between 2013 and 2015. In this systematic analysis, we 
produced estimates of the burden of neurological disorders 
(stroke, Alzheimer’s disease and other dementias, Parkinson’s 
disease, epilepsy, multiple sclerosis, migraine and tension-type 
headache, medication overuse headache, meningitis, tetanus, 
encephalitis, brain and nervous system cancers, motor neuron 
disease, and a residual category of other neurological disorders), 
separately and combined. For the first time, we included stroke, 
brain and nervous system cancer, and communicable 
neurological disorders. We quantified the global disease burden 
(as measured by prevalence, mortality, DALYs, years of life lost, 
and years lived with disability) and explored variation in the 
burden by neurological disorder type, age, sex, and overall 
country development level as measured by the Socio-
demographic Index (SDI). The study showed that neurological 
disorders ranked as the leading cause of DALYs in 2015 and the 
second-leading cause of death. The most prevalent neurological 
disorders were headaches (tension-type headache, medication 
overuse headache, and migraine) and Alzheimer’s disease and 
other dementias.
Implications of all the available evidence
Over the past 25 years, the burden of neurological disorders has 
increased substantially, and our expanded list of neurological 
disorders makes this the leading cause group of disability, and 
the second-leading cause group of mortality worldwide. Stroke 
remains the largest contributor to this burden globally. For all 
neurological disorders combined, there was a noticeable (by 
almost five times) gradual decrease in age-standardised DALY 
rates with increasing SDI, but these rates had large geographical 
variations. These findings could help to guide health systems 
and research activities to reduce the burden of neurological 
disorders.
See Online for appendix
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(DSM)-III and DSM-IV criteria for dementia and the 
International Classification of Headache Disorders 
criteria for headaches.5,6 Sources of information used to 
estimate the burden of neurological disorders are on the 
Global Health Data Exchange website.
Detailed GBD methods for calculating non-fatal 
estimates have been reported elsewhere.4 The epidemio-
logical data were analysed with DisMod-MR 2.1,7 a 
Bayesian meta-regression tool that adjusts datapoints for 
variations in study methods between data sources and 
enforces consistency between data for different 
parameters, such as incidence and prevalence. For each 
neurological disorder, we defined a parsimonious set of 
sequelae that best described different aspects of the 
disabling consequences. Each non-fatal sequela was 
estimated separately. We calculated the YLDs caused by 
the residual category of other neurological disorders 
indirectly using a ratio of YLDs to years of life lost (YLLs). 
We calculated the ratio of YLDs to YLLs for Alzheimer’s 
disease and other dementias, Parkinson’s disease, 
multiple sclerosis, and motor neuron disease, and 
multiplied this ratio by the YLL estimates for other 
neurological disorders. Further details of the non-fatal 
estimates of each of the included neurological disorders 
are in the appendix (pp 5–113).
Disability weights for a set of 235 health states covering 
all sequelae of disease and injury estimated in GBD 2015 
were estimated by pair-wise comparison methods 
presenting pairs of lay health state descriptions to 
respondents in surveys done in the general population in 
nine countries, and an open web-based survey.8 The 
sequelae of the neurological disorders included in this 
analysis each map to a unique health state with a 
corresponding disability weight (appendix pp 122–39). 
YLDs were computed by multiplying the prevalence of 
each sequela by a disability weight and aggregating 
estimates for all sequelae for a disease.
We categorised countries by their overall development 
status level as determined by the SDI, classifying them in 
high, high–medium, medium, medium–low, and low 
SDI quintiles on the basis of values across the 1980–2015 
period (appendix pp 142–46), as described in detail 
elsewhere.9 The average expected relationships between 
DALY rates and death rates from neurological disorders 
(individually and as a group) and SDI over the entire 
study period (1990–2015) across all geographies in males 
and females were estimated using spline regression. We 
also categorised countries into 21 GBD regions (appendix 
p 155).
Causes of death 
GBD 2015 uses a database of 14 236 site-years of vital 
registration, verbal autopsy (a method of determining 
cause of death in countries that have no functional vital 
registration system), and maternal and child death 
surveillance data, covering the period from 1980 to 2015.9 
Trained interviewers administer a structured 
questionnaire to relatives of a deceased person about 
their symptoms preceding death. The underlying cause 
of death is inferred by computer algorithms or physician 
review of the autopsy interview. We estimated deaths for 
all neurological disorders apart from headaches, to 
which no deaths are assigned as the underlying cause. 
For each neurological cause except dementia, we used 
the GBD Cause of Death Ensemble model (CODEm) 
strategy.10,11 CODEm applies mixed effects or spatio-
temporal Gaussian process regression models to 
mortality rates or cause fractions in varying com-
binations with predictive covariates. The ensemble of 
models with best credentials on out-of-sample predictive 
validity tests was selected for each cause of death. YLLs 
were calculated by multiplying the number of deaths at 
each age by the standard life expectancy at that age.12 
Results from CODEm for each disease were scaled to fit 
all-cause mortality estimates derived from demographic 
sources by location, age, year, and sex.
We decided to use a natural history model for 
dementia because of a large inconsistency between the 
data for prevalence and mortality. For instance, in the 
USA, the rates of death from dementia increased five 
times between 1990 and 2014, whereas the available 
prevalence and incidence data showed no significant 
changes over the same period. Large increases in death 
rates assigned to dementia have also occurred in some 
other countries with high-quality vital registration 
systems. Furthermore, in GBD 2015, the prevalence of 
dementia varied among 187 countries by a factor of 
three, whereas dementia death rates varied by more 
than 20 times.13 The likely explanation was a change in 
coding practices between countries and within countries 
over time. To correct for this source of measurement 
bias, we assessed the most recent data from 23 high-
income countries with high-quality vital registration 
systems and the highest ratio of registered dementia 
death rates to prevalent cases. This ratio is equivalent to 
the excess rate of mortality in cases of dementia. We 
derived a pooled estimate by age and sex using a linear 
regression of the log of these rates. We added these 
estimates as data in DisMod-MR 2.1 to derive estimates 
of cause-specific mortality rates that were consistent 
with prevalence data and the pooled estimate of excess 
mortality from the 23 countries that in their most recent 
year of vital registration were most willing to code a 
death to dementia as the underlying cause.10 
Compilation of results
DALYs were computed as the sum of YLLs and YLDs for 
each country, age, sex, and year with 95% uncertainty 
intervals (UIs) based on the 25th and 975th values of the 
ordered 1000 draws. Unless explicitly mentioned 
otherwise, all rates were age-standardised using the 
GBD standard.10 This study is compliant with the 
Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER; appendix pp 114–17).14,15
For more on the Global Health 
Data Exchange see http://ghdx.
healthdata.org/gbd-2015/data-
input-sources
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Global burden
In 2015, the neurological disorders included in this 
analysis caused 250·692 (95% UI 229·080 to 274·654) 
million DALYs, comprising 10·2% of global DALYs, and 
9·399 (9·095 to 9·714) million deaths, comprising 16·8% 
All-age numbers (thousands) Age-standardised rate (per 100  000)
2015 Change from 1990 to 2015 2015 Change from 1990 to 2015
Tetanus
DALYs 3510 (3002 to 4503) –86·3% (–88·1 to –83·3) 47 (40 to 61) –87·4% (–89·0 to –84·9)
Deaths 57 (48 to 80) –83·4% (–85·5 to –78·8) 1 (1 to 1) –85·7% (–87·5 to –82·4)
Prevalence 209 (205 to 215) 10·6% (5·1 to 15·2) 3 (3 to 3) –15·4% (–19·6 to –12·3)
Meningitis
DALYs 25 395 (21 653 to 30 649) –31·9% (–42·6 to –10·1) 342 (292 to 413) –39·8% (–48·8 to –22·0)
Deaths 379 (323 to 445) –25·2% (–35·6 to –4·2) 5 (5 to 6) –38·5% (–45·9 to –23·7)
Prevalence 8734 (8321 to 9107) 27·9% (24·3 to 31·7) 120 (114 to 125) –10·6% (–13·2 to –8·0)
Encephalitis
DALYs 8453 (7669 to 9412) –14·0% (–25·8 to –0·1) 115 (104 to 128) –29·0% (–38·4 to –18·7)
Deaths 150 (138 to 167) –3·4% (–15·4 to 10·9) 2 (2 to 2) –29·6% (–38·1 to –20·1)
Prevalence 4316 (3146 to 5876) 13·5% (9·3 to 19·2) 59 (43 to 80) –23·7% (–26·9 to –19·2)
Stroke
DALYs 118 627 (114 862 to 122 627) 21·7% (17·8 to 25·7) 1777 (1721 to 1835) –32·3% (–34·4 to –30·0)
Deaths 6326 (6175 to 6493) 36·4% (32·4 to 40·8) 101 (99 to 104) –30·0% (–32·0 to –27·7)
Prevalence 42 431 (42 068 to 42 767) 59·2% (58·4 to 59·9) 627 (621 to 631) –9·8% (–10·3 to –9·4)
Alzheimer’s disease and other dementias
DALYs 23 779 (20 118 to 27 886) 98·4% (95·0 to 101·9) 396 (334 to 464) –5·7% (–7·2 to –4·2)
Deaths 1908 (1587 to 2229) 114·9% (111·1 to 119·6) 32 (27 to 38) –3·4% (–4·8 to –1·4)
Prevalence 45 956 (40 179 to 52 656) 111·7% (109·1 to 114·2) 761 (663 to 876) 2·4% (1·7 to 3·2)
Parkinson’s disease
DALYs 2059 (1832 to 2321) 111·2% (102·4 to 118·1) 33 (30 to 37) 10·8% (6·5 to 14·3)
Deaths 117 (114 to 121) 149·8% (135·0 to 161·4) 2 (2 to 2) 22·6% (15·7 to 28·4)
Prevalence 6193 (5726 to 6777) 117·8% (113·2 to 122·8) 98 (90 to 107) 15·7% (13·3 to 18·3)
Epilepsy
DALYs 12 418 (10 438 to 14 479) 2·5% (–5·7 to 11·2) 168 (141 to 195) –22·5% (–28·2 to –16·8)
Deaths 125 (119 to 131) 18·9% (6·4 to 32·1) 2 (2 to 2) –15·6% (–23·0 to –8·0)
Prevalence 23 415 (21 550 to 25 419) 39·2% (33·4 to 45·2) 320 (295 to 347) 1·9% (–2·1 to 6·1)
Multiple sclerosis
DALYs 1234 (1033 to 1437) 42·4% (31·8 to 57·3) 17 (14 to 20) –16·0% (–22·1 to –7·6)
Deaths 19 (17 to 20) 39·9% (24·9 to 61·6) 0 (0 to 0) –21·4% (–29·1 to –10·8)
Prevalence 2012 (1866 to 2167) 59·0% (55·5 to 62·6) 28 (26 to 30) –4·6% (–6·7 to –2·5)
Migraine
DALYs 32 899 (20 295 to 48 945) 49·5% (46·8 to 52·3) 439 (271 to 654) 0·5% (–0·5 to 1·5)
Deaths ·· ·· ·· ··
Prevalence 958 789 (872 109 to 1 055 631) 49·6% (46·9 to 52·3) 12 799 (11 651 to 14 065) 0·1% (–0·9 to 1·1)
Tension-type headache
DALYs 2261 (1055 to 4193) 49·2% (46·0 to 52·5) 30 (14 to 56) 0·2% (–1·0 to 1·4)
Deaths ·· ·· ·· ··
Prevalence 1 505 892 (1 337 310 to 1 681 575) 49·2% (46·1 to 52·5) 20 121 (17 924 to 22 442) 0·0 (–1·1 to 1·2)
Medication overuse headache
DALYs 9165 (6089 to 13081) 57·7% (52·5 to 63·3) 124 (82 to 177) –0·9% (–3·9 to 2·2)
Deaths ·· ·· ·· ··
Prevalence 58 455 (50 835 to 67 364) 57·8% (52·6 to 63·3) 790 (690 to 907) –1·2% (–4·2 to 1·8)
(Table 1 continues on next page)
Articles
www.thelancet.com/neurology   Vol 16   November 2017 881
of global deaths. We were unable to report the combined 
prevalence. Classifying stroke under neurological 
disorders rather than cardiovascular diseases made 
neurological disorders the largest cause group of DALYs 
and the second-largest behind cardiovascular diseases in 
terms of global deaths. Among the neurological 
disorders, stroke, migraine, meningitis, Alzheimer’s 
disease and other dementias, and epilepsy each caused 
more than 10 million DALYs. The most prevalent 
neurological disorders were the various types of headache 
and Alzheimer’s disease and other dementias (table 1).
Global burden by sex and age
Substantial sex differences in age-standardised death, 
DALY, and prevalence rates existed globally in 2015. 
The only neurological disorders with less than 
10% difference between males and females were 
Alzheimer’s disease and other dementias in terms of 
death and DALY rates, and meningitis and epilepsy in 
terms of prevalence rate. Apart from multiple sclerosis, 
Alzheimer’s disease and other dementias, and the three 
headache types, DALY and prevalence rates were higher 
in males than females. All these more substantial sex 
differences were significant apart from those for 
meningitis, tetanus, and encephalitis death rates and 
the meningitis and encephalitis DALY rates (appendix 
pp 153–54). The age pattern varied between the various 
neurological disorders. The bulk of burden due to 
communicable neurological disorders occurred in 
young individuals, particularly the 0–5 years age group. 
Epilepsy caused the most burden in children and young 
adults. Headaches peaked at ages 25–49 years, whereas 
the burden of other neurological disorders increased 
with age (figure 1).
Proportional contribution to the combined burden
Stroke accounted for the largest proportion of total 
DALYs (47·3%) and deaths (67·3%) among all 
neurological disorders analysed (figure 2). Migraine, 
meningitis, and Alzheimer’s disease and other dementias 
were the second, third, and fourth largest contributors of 
DALYs. The proportional contributions of the other 
neurological disorders analysed were less substantial and 
varied from 0·4% (for motor neuron disease) to 5·0% 
(epilepsy). The second largest contributor to deaths from 
neurological disorders was Alzheimer’s disease and 
other dementias. The proportional contribution of deaths 
from other neurological disorders varied from 0·2% for 
(multiple sclerosis) to 4·0% (for meningitis; figure 2).
Geographical variations in the burden
In 2015, the lowest age-standardised DALY rates (less 
than 3000 per 100 000 people) and death rates (less than 
100 per 100 000 people) from neurological disorders were 
estimated for high-income regions and Latin America, 
whereas the highest DALY rates (more than 7000 per 
100 000 people) were estimated for Afghanistan, Central 
African Republic, Guinea-Bissau, Kiribati, and Somalia. 
The highest death rates (more than 280 per 100 000 people) 
were estimated for Afghanistan and the Central African 
Republic (figure 3).
Stroke was the leading cause of age-standardised DALY 
rates in 18 of 21 GBD regions, while migraine and 
Alzheimer’s disease and other dementias were ranked 
All-age numbers (thousands) Age-standardised rate (per 100 000)
2015 Change from 1990 to 2015 2015 Change from 1990 to 2015
(Continued from previous page)
Motor neuron disease
DALYs 910 (872 to 959) 56·1% (34·6 to 69·6) 13 (13 to 14) –0·9% (–12·4 to 4·0)
Deaths 35 (34 to 37) 97·3% (73·9 to 103·6) 1 (1 to 1) 12·7% (0·5 to 15·9)
Prevalence 202 (190 to 216) 72·4% (69·2 to 75·2) 3 (3 to 3) 3·1% (1·5 to 4·7)
Brain and nervous system cancer
DALYs 7624 (6975 to 8219) 37·5% (16·9 to 54·1) 106 (97 to 114) –9·0% (–21·1 to 0·8)
Deaths 229 (210 to 245) 65·8% (42·2 to 78·2) 3 (3 to 4) –0·4% (–13·5 to 6·4)
Prevalence 1205 (1102 to 1323) 60·2% (31·7 to 87·2) 17 (16 to 19) 8·9% (–7·2 to 24·0)
Other neurological disorders*
DALYs 2360 (2217 to 2565) 31·7% (19·1 to 40·5) 34 (31 to 36) –9·4% (–15·8 to –5·7)
Deaths 54 (53 to 58) 53·1% (42·9 to 58·4) 1 (1 to 1) –5·2% (–10·5 to –1·9)
All neurological disorders
DALYs 250 692 (229 080 to 274 654) 7·4%† 3639 (3342 to 3964) –29·7%†
Deaths 9399 (9095 to 9714) 36·7%† 150 (145 to 155) –26·1%†
Data are n or % with 95% uncertainty intervals (UIs). Prevalence is an aggregate of all sequelae for a condition. DALYs=disability-adjusted life-years. *Includes muscular 
dystrophy, Huntington’s disease, and other less common neurological disorders (appendix p 112). †UIs were not calculated for aggregated estimates of percentage change as 
this was not built into the Global Burden of Disease Study 2015 computational machinery and would have required a large computational effort competing with demands of 
completing the Global Burden of Disease Study 2016.  
Table 1: Global absolute numbers and age-standardised rates per 100 000 people for neurological disorders and percentage changes between 1990 and 2015 
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among the top three causes in all regions except 
Oceania, south Asia, and the four sub-Saharan African 
regions, where epilepsy or meningitis ranked higher. 
Communicable neurological conditions ranked low in 
high-income regions and central Europe. Epilepsy and 
medication overuse headache ranked fourth, fifth, or 
sixth in almost all regions (figure 4).
A more detailed breakdown of geographical variation 
is shown as maps of age-standardised prevalence, death 
rates, and DALY rates for each neurological disorder 
(appendix pp 156–69). The prevalence of stroke was 
highest in eastern Europe, central Asia, Oceania, 
Indonesia, Myanmar, and sub-Saharan African 
countries. High death rates in Mongolia, Afghanistan, 
and Central African Republic were responsible for these 
countries also having the highest age-standardised 
DALY rates for stroke. Prevalence, death, and DALY 
rates for Alzheimer’s and other dementias were highest 
in North America and north Africa and the Middle East, 
while the lowest rates were estimated for sub-Saharan 
Africa, southern Latin America, and Australasia. 
Prevalence and DALY rates for Parkinson’s disease were 
highest in high-income regions and lowest in sub-
Saharan Africa and eastern Europe. The strong positive 
relationship with latitude was apparent in the 
distribution of prevalence, death, and DALY rates for 
multiple sclerosis. High death rates due to epilepsy 
were the cause of high DALY rates in sub-Saharan 
Africa. Prevalence of epilepsy was highest in central 
Latin America, Chile, north Africa and the Middle East, 
and Bangladesh. Highest rates of motor neuron disease 
occurred in high-income regions.
The prevalence and DALY rates for the different types 
of headache varied by a factor of three to four between 
countries with the highest rates in high-income regions, 
north Africa and the Middle East, and tropical 
Latin America, while lowest rates were seen in sub-
Saharan Africa and east Asia. Medication overuse 
headache was particularly common in eastern Europe 
and Iran. The highest death and DALY rates for brain 
and nervous system cancers were in central Europe and 
north Africa and the Middle East. Meningitis caused 
most disease burden in sub-Saharan Africa, especially in 
the meningitis belt across the Sahara. The largest burden 
Figure 1: Global DALYs by age and neurological disorder in 2015
DALYs=disability-adjusted life-years.
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from tetanus was estimated for a few countries in east 
Africa, particularly South Sudan and Somalia, which 
have low vaccination coverage owing to national conflict. 
India had the largest burden from encephalitis.
Changes in the burden from 1990 to 2015
Time trends from 1990 to 2015 in prevalence, deaths, and 
DALYs due to neurological disorders varied across the 
disorders studied (table 1). Despite a significant drop in 
age-standardised stroke rates, population increase and 
ageing combined led to increases in absolute numbers of 
the three indicators. There was a large increase in the 
absolute numbers of DALYs, deaths, and prevalent cases 
of Alzheimer’s disease and other dementias even though 
the changes in age-standardised rates were small. For 
Parkinson’s disease, the numbers of DALYs, deaths, and 
prevalent cases increased substantially while increases in 
age-standardised rates were more modest. There was a 
significant decrease in epilepsy death and DALY rates 
while the age-standardised prevalence rate remained 
stable. DALYs, deaths, and prevalent cases of multiple 
sclerosis increased despite decreasing age-standardised 
rates. The absolute numbers of DALYs and prevalent 
cases of motor neuron disease, brain cancer, and 
headaches increased substantially while there was little 
change in age-standardised rates. The largest decreases 
were observed in communicable neurological disorders 
(tetanus, meningitis, and encephalitis). Although the 
rates of DALYs and deaths for all neurological disorders 
combined decreased by more than a quarter from 
1990 to 2015, the absolute number of DALYs and deaths 
from all neurological disorders combined over that 
period increased by 7·4% (from 233·4 million to 
250·7 million) and 36·7% (from 6·9 million to 
9·4 million), respectively.
The decrease in DALY rates from 1990 to 2015 was 
estimated for most countries. The only countries 
with an increase in age-standardised DALY rates were 
the Philippines, Mongolia, Lesotho, Swaziland, and 
Zimbabwe, largely because these countries had an 
increase in DALYs from stroke over the 25-year period. 
The age-standardised DALY rates from neurological 
disorders dropped by more than half in Ethiopia, 
Equatorial Guinea, and South Korea (table 2).
Global burden by SDI
The patterns of disease varied along the development 
spectrum as measured by the SDI (figure 5). Age-
standardised DALY rates of communicable neurological 
disorders were the largest cause of DALYs at low levels 
of SDI. Stroke rates increased from low to middle levels 
of SDI and then decreased to their lowest values at the 
highest level of SDI. The headaches showed little 
change in rates with SDI. Rates of epilepsy gradually 
decreased with rising SDI (figure 5A). However, the all-
age rates of combined neurological disorders increased 
from middle range to highest SDI values, particularly in 
females (figure 5B). Most of the changes in DALY rates 
of neurological disorders with development were driven 
by changes in YLLs. By comparison, the burden due to 
YLDs showed less variation over the range of SDI 
(figure 5C).
Figure 2: Contribution of various neurological disorders to the overall burden from neurological disorders in 2015
Estimates are for (A) disability-adjusted life-years and (B) deaths.
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Figure 3: Age-standardised rates of (A) DALYs and (B) deaths per 100 000 people from all neurological disorders combined in 2015
Data are for both sexes. DALYs=disability-adjusted life-years. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. Marshall 
Isl=Marshall Islands. Sol Isl=Solomon Islands. FSM=Federated States of Micronesia. 
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On the basis of SDI, Oceania, east and southeast Asia, 
eastern and central Europe, and central Asia had higher 
than expected age-standardised DALY rates for stroke 
for males over the entire estimation period. In females, 
the stroke DALY rates followed the same pattern but 
crossed the expected line in a few years of estimation. In 
females, the stroke DALY rates were initially higher 
than expected on the basis of SDI but fell to below 
expected levels during the study period. Latin America, 
apart from tropical Latin America in the 1990s, eastern 
and western sub-Saharan Africa, western Europe, 
Australasia, and high-income North America had lower 
DALY rates than expected based on SDI (appendix p 
170). North Africa and the Middle East had higher than 
expected DALY rates for Alzheimer’s disease and other 
dementias for males and females. Females in central 
sub-Saharan Africa, high-income North America, and 
tropical Latin America had DALY rates close to expected 
for their SDI values, while all other regions had much 
lower than expected rates (appendix p 171). Migraine 
DALY rates in males in south Asia were furthest above 
the expected line based on SDI. In females, migraine 
DALY rates in tropical Latin America, south Asia, 
Australasia, western Europe, and high-income North 
America were higher than expected. East Asia had much 
lower DALY rates of migraine than expected in males 
and females (appendix p 172). Epilepsy DALY rates were 
higher than expected in eastern, southern, and central 
sub-Saharan Africa and central Asia. Epilepsy rates were 
a bit lower than expected in Oceania and east Asia. The 
DALY rates for meningitis were higher than expected 
based on SDI in western sub-Saharan Africa. All other 
regions closely followed the expected pattern (appendix 
p 173). Plots of regional age-standardised DALY rates 
and SDI for the remaining neurological disorders are in 
the appendix (pp 174–83).
Discussion
Neurological disorders including stroke, communicable 
neurological diseases, and brain cancer accounted for 
10·2% of global DALYs and 16·8% of all deaths in 2015. 
DALYs from all neurological disorders combined exceeded 
those from all injuries (249·8 million), cardiovascular 
disease (228·9 million, excluding stroke), cancer 
(209·4 million), and mental and substance use disorders 
(162·4 million).3 Our study provides a comprehensive 
assessment of the extent, patterns, and trends of DALYs 
for the combined neurological disorders at global, 
regional, and national levels for 195 countries and 
territories with important implications for health policy, 
including priority-setting and financing of health services.
Despite an overall decrease in the age-standardised 
rates of DALYs, death, and YLDs of all neurological 
disorders combined between 1990 and 2015, the number 
of people dying from and affected by these disorders has 
increased substantially, contributing to higher health 
loss across the lifespan. Parkinson’s disease was the only 
neurological disorder with increasing age-standardised 
rates of deaths, prevalence, and DALYs between 1990 
and 2015. Although the burden of communicable 
neurological disorders has significantly decreased over 
this period, the burden of non-communicable neuro-
logical disorders has significantly increased. This finding 
is consistent with the overall global burden shift from 
communicable to non-communicable disorders.16 In 
terms of absolute number of people affected by 
neurological disorders, most of the increase in the 
burden was associated with ageing of the population and 
population growth.9 Increasing incidence of stroke in 
low-income and middle-income countries,17 increasing 
prevalence of multiple sclerosis,18,19 increasing incidence 
of epilepsy in elderly people,20 increasing prevalence of 
tension-type headache,21 and increasing incidence of 
Figure 4: Ranking of age-standardised DALY rates for all neurological disorders by GBD region in 2015
Data are for both sexes. DALYs=disability-adjusted life-years.
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brain tumours in elderly people22 have been reported 
elsewhere. Findings from other studies have reported 
that it is difficult to assess trends in prevalence and 
incidence of Parkinson’s disease because of changes in 
case definitions over time.23,24 The evidence on secular 
trends in prevalence of migraine is mixed.21,25
The conclusions from a systematic review26 of similar 
studies over time to examine trends in prevalence, 
incidence, and mortality for people with dementia were 
that there is some evidence that the incidence of 
dementia might be declining in high-income countries, 
but evidence on trends in the prevalence of dementia is 
inconsistent. Our study showed a modest increase in 
the prevalence of Alzheimer’s disease and other 
dementias in high-income North America, high-income 
Asia Pacific, east Asia, south Asia, the Caribbean, and 
All-age DALYs (thousands) Age-standardised rate of DALYs (per 100 000)
1990 2015 Change from 
1990 to 2015*
1990 2015 Change from 
1990 to 2015*
Afghanistan 1535 (1057 to 2053) 2071 (1667 to 2553) 34·9% 12 255 (9773 to 14 594) 10 669 (8798 to 12 830) –12·9%
Albania 108 (97 to 120) 121 (108 to 135) 12·2% 4395 (4033 to 4804) 3691 (3287 to 4101) –16·0%
Algeria 822 (707 to 961) 1107 (950 to 1267) 34·7% 4608 (4104 to 5162) 3462 (3021 to 3915) –24·9%
Andorra 1 (1 to 2) 2 (2 to 3) 62·8% 2146 (1791 to 2536) 1766 (1435 to 2132) –17·7%
Angola 871 (523 to 1284) 1067 (647 to 1956) 22·4% 8642 (4399 to 14 190) 6273 (3302 to 13 343) –27·4%
Antigua and Barbuda 2 (2 to 2) 2 (2 to 3) 8·8% 4170 (3783 to 4612) 2866 (2516 to 3259) –31·3%
Argentina 997 (908 to 1099) 977 (853 to 1118) –2·0% 3310 (3029 to 3644) 2152 (1873 to 2470) –35·0%
Armenia 108 (96 to 120) 108 (97 to 121) 0 3878 (3519 to 4253) 3101 (2782 to 3487) –20·0%
Australia 448 (392 to 513) 572 (490 to 667) 27·6% 2529 (2209 to 2897) 1877 (1571 to 2237) –25·8%
Austria 300 (270 to 336) 263 (227 to 303) –12·5% 3022 (2661 to 3434) 2046 (1701 to 2431) –32·3%
Azerbaijan 240 (219 to 266) 309 (274 to 350) 28·7% 4940 (4576 to 5348) 3619 (3242 to 4046) –26·7%
Bahrain 10 (8 to 12) 21 (17 to 26) 110·8% 3231 (2800 to 3697) 2222 (1856 to 2627) –31·2%
Bangladesh 6545 (5715 to 7383) 6416 (5551 to 7253) –2·0% 7004 (6347 to 7682) 5344 (4667 to 5998) –23·7%
Barbados 10 (9 to 11) 10 (9 to 11) 3·1% 3768 (3404 to 4168) 2760 (2411 to 3123) –26·7%
Belarus 486 (444 to 529) 519 (474 to 572) 6·8% 4414 (4021 to 4831) 3906 (3536 to 4328) –11·5%
Belgium 377 (341 to 420) 374 (328 to 426) –0·6% 2954 (2624 to 3338) 2181 (1847 to 2562) –26·2%
Belize 5 (4 to 5) 7 (6 to 9) 52·4% 3647 (3275 to 4045) 3055 (2681 to 3453) –16·2%
Benin 330 (227 to 449) 431 (307 to 606) 30·7% 5984 (4947 to 7160) 5443 (3617 to 8060) –9·0%
Bhutan 34 (25 to 44) 22 (18 to 26) –34·8% 6145 (5110 to 7428) 3525 (2930 to 4167) –42·6%
Bolivia 251 (217 to 299) 258 (219 to 302) 2·7% 4444 (3949 to 5024) 2941 (2514 to 3412) –33·8%
Bosnia and Herzegovina 165 (148 to 183) 151 (135 to 169) –8·8% 4323 (3931 to 4737) 2927 (2592 to 3313) –32·3%
Botswana 33 (19 to 62) 61 (31 to 157) 84·3% 4495 (2344 to 8776) 4312 (2204 to 10667) –4·1%
Brazil 4947 (4480 to 5482) 5874 (5149 to 6669) 18·7% 4988 (4619 to 5392) 3100 (2753 to 3480) –37·9%
Brunei 5 (4 to 6) 8 (7 to 9) 57·6% 3414 (3080 to 3798) 2477 (2190 to 2796) –27·4%
Bulgaria 570 (536 to 607) 458 (424 to 492) –19·7% 5401 (5059 to 5782) 3870 (3531 to 4237) –28·4%
Burkina Faso 647 (482 to 880) 750 (552 to 1010) 16·0% 5990 (4957 to 7341) 4633 (3380 to 6265) –22·6%
Burundi 453 (337 to 573) 470 (341 to 644) 3·7% 10 962 (7640 to 14 124) 5627 (3938 to 7954) –48·7%
Cambodia 536 (440 to 674) 468 (404 to 531) –12·7% 7223 (6409 to 8176) 4512 (3938 to 5061) –37·5%
Cameroon 595 (458 to 785) 865 (622 to 1200) 45·4% 5384 (4559 to 6359) 5148 (3530 to 7428) –4·4%
Canada 724 (628 to 834) 984 (850 to 1130) 35·8% 2473 (2148 to 2844) 1999 (1685 to 2350) –19·1%
Cape Verde 12 (10 to 14) 14 (12 to 16) 13·3% 4867 (4433 to 5327) 3577 (3086 to 4219) –26·5%
Central African Republic 221 (173 to 269) 305 (197 to 439) 38·1% 9138 (7601 to 10697) 8838 (5307 to 13 092) –3·3%
Chad 474 (349 to 634) 787 (555 to 1108) 66·2% 6416 (5233 to 7779) 6128 (4089 to 8876) –4·5%
Chile 359 (318 to 406) 438 (382 to 501) 22·1% 3420 (3088 to 3784) 2223 (1926 to 2551) –35·0%
China 45 845 (42 895 to 48 907) 49 486 (46 074 to 53 228) 7·9% 5529 (5208 to 5880) 3410 (3181 to 3658) –38·3%
Colombia 826 (729 to 933) 949 (806 to 1112) 15·0% 3361 (3033 to 3710) 2244 (1928 to 2580) –33·2%
Comoros 24 (18 to 31) 23 (17 to 30) –5·0% 7384 (5104 to 10 202) 4378 (3200 to 5834) –40·7%
Congo (Brazzaville) 117 (92 to 146) 166 (117 to 225) 41·4% 7457 (6021 to 9064) 5566 (3793 to 7795) –25·4%
Costa Rica 59 (50 to 68) 93 (78 to 109) 58·6% 2594 (2272 to 2954) 1996 (1684 to 2335) –23·1%
Cote d’Ivoire 594 (475 to 735) 848 (614 to 1130) 42·9% 5778 (4923 to 6704) 5377 (3750 to 7587) –6·9%
Croatia 234 (218 to 253) 192 (175 to 210) –18·0% 4309 (3986 to 4667) 2871 (2554 to 3217) –33·4%
(Table 2 continues on next page)
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All-age DALYs (thousands) Age-standardised rate of DALYs (per 100 000)
1990 2015 Change from 
1990 to 2015*
1990 2015 Change from 
1990 to 2015*
(Continued from previous page)
Cuba 324 (291 to 362) 379 (337 to 425) 16·7% 3295 (2976 to 3645) 2583 (2276 to 2944) –21·6%
Cyprus 20 (18 to 22) 21 (18 to 25) 8·1% 2962 (2627 to 3321) 1922 (1593 to 2284) –35·1%
Czech Republic 519 (483 to 561) 355 (315 to 400) –31·7% 4376 (4039 to 4748) 2311 (2007 to 2657) –47·2%
Democratic Republic of the 
Congo
1730 (1316 to 2183) 2976 (2197 to 3938) 72·0% 5934 (4390 to 7735) 5521 (3927 to 7317) –7·0%
Denmark 204 (184 to 226) 184 (162 to 207) –9·9% 3032 (2707 to 3425) 2286 (1967 to 2644) –24·6%
Djibouti 27 (20 to 35) 34 (22 to 52) 26·7% 5845 (4301 to 7885) 5047 (3271 to 7902) –13·7%
Dominica 2 (2 to 2) 2 (2 to 2) 7·1% 3479 (3103 to 3902) 3022 (2645 to 3436) –13·1%
Dominican Republic 198 (174 to 222) 265 (231 to 301) 33·6% 3657 (3289 to 4039) 3038 (2691 to 3408) –16·9%
Ecuador 246 (216 to 275) 326 (279 to 380) 32·8% 3266 (2917 to 3623) 2382 (2063 to 2734) –27·1%
Egypt 2393 (2172 to 2607) 2696 (2395 to 3068) 12·6% 5267 (4828 to 5746) 3963 (3581 to 4494) –24·8%
El Salvador 139 (124 to 156) 118 (99 to 139) –15·0% 3516 (3166 to 3892) 2105 (1788 to 2461) –40·1%
Equatorial Guinea 30 (17 to 47) 29 (18 to 55) –3·5% 9305 (4456 to 15829) 4487 (2798 to 9079) –51·8%
Eritrea 219 (161 to 281) 213 (146 to 314) –3·0% 9041 (7575 to 10 688) 6369 (3831 to 9981) –29·6%
Estonia 86 (79 to 92) 50 (44 to 56) –42·1% 4813 (4451 to 5213) 2464 (2130 to 2836) –48·8%
Ethiopia 4344 (2923 to 5858) 3387 (2546 to 4404) –22·0% 9284 (7605 to 10967) 4637 (3343 to 6232) –50·1%
Federated States of Micronesia 3 (3 to 4) 3 (2 to 4) –15·6% 5884 (4146 to 7785) 4216 (3098 to 6093) –28·4%
Fiji 24 (21 to 27) 28 (24 to 32) 15·7% 5429 (4749 to 6247) 3882 (3380 to 4409) –28·5%
Finland 197 (178 to 219) 198 (175 to 224) 0·2% 3287 (2936 to 3678) 2309 (1980 to 2701) –29·8%
France 1743 (1546 to 1966) 1901 (1658 to 2170) 9·1% 2493 (2169 to 2845) 1948 (1642 to 2305) –21·8%
Gabon 44 (37 to 53) 53 (41 to 73) 20·4% 5763 (4886 to 6694) 4289 (3185 to 5984) –25·6%
Georgia 289 (265 to 312) 222 (203 to 247) –23·0% 5268 (4847 to 5707) 4236 (3825 to 4740) –19·6%
Germany 3115 (2799 to 3455) 2748 (2400 to 3123) –11·8% 2973 (2627 to 3343) 2041 (1711 to 2401) –31·4%
Ghana 687 (549 to 853) 941 (644 to 1342) 36·9% 6309 (4812 to 8167) 5071 (3277 to 7649) –19·6%
Greece 430 (394 to 470) 447 (403 to 496) 3·9% 3366 (3046 to 3735) 2365 (2058 to 2734) –29·7%
Greenland 2 (2 to 2) 1 (1 to 2) –20·7% 4929 (4464 to 5370) 3214 (2843 to 3616) –34·8%
Grenada 4 (3 to 4) 3 (3 to 4) –10·4% 4941 (4534 to 5365) 3714 (3350 to 4139) –24·8%
Guatemala 191 (166 to 218) 304 (257 to 355) 59·6% 2874 (2531 to 3251) 2495 (2136 to 2865) –13·2%
Guinea 558 (399 to 753) 550 (413 to 722) –1·3% 7288 (5950 to 8810) 5719 (4215 to 7617) –21·5%
Guinea–Bissau 87 (57 to 130) 121 (71 to 218) 40·0% 7587 (4479 to 13 190) 7463 (3972 to 15 833) –1·6%
Guyana 32 (29 to 35) 27 (24 to 31) –14·2% 7121 (6584 to 7631) 4805 (4309 to 5343) –32·5%
Haiti 515 (441 to 624) 437 (358 to 525) –15·0% 8584 (7695 to 9626) 5696 (4751 to 6682) –33·6%
Honduras 224 (198 to 247) 210 (179 to 243) –6·4% 4773 (4368 to 5208) 3530 (3022 to 4104) –26·0%
Hungary 585 (545 to 626) 382 (343 to 424) –34·7% 4697 (4357 to 5065) 2567 (2250 to 2906) –45·3%
Iceland 7 (6 to 8) 8 (7 to 9) 16·4% 2607 (2286 to 2973) 1976 (1653 to 2345) –24·2%
India 49 938 (45 989 to 54 561) 45 738 (40 949 to 51 065) –8·4% 6590 (6135 to 7129) 4274 (3881 to 4706) –35·2%
Indonesia 7770 (6393 to 9192) 9914 (8424 to 11268) 27·6% 5930 (5238 to 6639) 5115 (4375 to 5773) –13·7%
Iran 1618 (1379 to 1855) 2033 (1664 to 2395) 25·7% 4596 (4042 to 5149) 3411 (2871 to 3950) –25·8%
Iraq 640 (544 to 757) 1045 (875 to 1257) 63·2% 5733 (4939 to 6610) 4989 (4150 to 5944) –13·0%
Ireland 101 (89 to 116) 111 (94 to 130) 9·3% 2811 (2446 to 3212) 2039 (1703 to 2412) –27·4%
Israel 109 (96 to 125) 169 (143 to 199) 55·2% 2693 (2370 to 3069) 1968 (1642 to 2340) –26·9%
Italy 2182 (1936 to 2447) 2378 (2058 to 2712) 9·0% 2991 (2611 to 3410) 2211 (1832 to 2637) –26·1%
Jamaica 81 (73 to 89) 89 (79 to 101) 10·1% 4074 (3706 to 4489) 3249 (2873 to 3671) –20·2%
Japan 3650 (3267 to 4087) 4489 (3999 to 5046) 23·0% 2587 (2302 to 2914) 1838 (1571 to 2163) –29·0%
Jordan 76 (64 to 88) 129 (106 to 155) 69·9% 4125 (3579 to 4701) 2683 (2278 to 3104) –35·0%
Kazakhstan 657 (605 to 720) 691 (623 to 765) 5·1% 5161 (4805 to 5562) 4518 (4102 to 4954) –12·4%
Kenya 1143 (953 to 1509) 1427 (1222 to 1699) 24·9% 5323 (4608 to 6314) 4160 (3648 to 4684) –21·9%
Kiribati 5 (4 to 6) 6 (5 to 7) 19·1% 8788 (7712 to 9853) 7420 (6390 to 8508) –15·6%
Kuwait 30 (24 to 37) 59 (45 to 74) 94·5% 2447 (2078 to 2867) 2372 (1982 to 2802) –3·1%
(Table 2 continues on next page)
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All-age DALYs (thousands) Age-standardised rate of DALYs (per 100 000)
1990 2015 Change from 
1990 to 2015*
1990 2015 Change from 
1990 to 2015*
(Continued from previous page)
Kyrgyzstan 189 (174 to 205) 211 (190 to 234) 11·4% 6102 (5662 to 6542) 5062 (4661 to 5540) –17·1%
Laos 327 (255 to 425) 221 (186 to 263) –32·4% 8564 (7132 to 10059) 4735 (4058 to 5497) –44·7%
Latvia 160 (150 to 171) 112 (103 to 122) –29·9% 5136 (4784 to 5534) 3308 (2963 to 3682) –35·6%
Lebanon 79 (67 to 91) 129 (104 to 155) 64·0% 3729 (3182 to 4297) 2421 (1969 to 2877) –35·1%
Lesotho 45 (34 to 56) 79 (52 to 115) 74·2% 4296 (3155 to 5366) 6037 (3841 to 8956) 40·5%
Liberia 160 (115 to 224) 154 (115 to 212) –4·0% 6601 (5212 to 8374) 4590 (3327 to 6043) –30·5%
Libya 115 (99 to 131) 151 (128 to 176) 32·1% 3690 (3248 to 4146) 3324 (2880 to 3808) –9·9%
Lithuania 142 (129 to 156) 132 (119 to 145) –6·8% 3550 (3227 to 3926) 2843 (2522 to 3193) –19·9%
Luxembourg 16 (15 to 18) 15 (13 to 18) –4·8% 3480 (3113 to 3879) 2137 (1789 to 2551) –38·6%
Macedonia 91 (84 to 99) 102 (93 to 112) 12·1% 5554 (5179 to 5963) 4160 (3765 to 4547) –25·1%
Madagascar 648 (525 to 783) 925 (662 to 1286) 42·7% 7517 (6553 to 8475) 6186 (4189 to 8857) –17·7%
Malawi 661 (472 to 950) 604 (452 to 810) –8·6% 6512 (5245 to 8155) 4212 (3071 to 5691) –35·3%
Malaysia 437 (389 to 484) 689 (592 to 789) 57·8% 4020 (3696 to 4359) 2925 (2555 to 3305) –27·3%
Maldives 5 (4 to 6) 5 (4 to 6) –0·2% 3712 (3308 to 4173) 2011 (1700 to 2359) –45·8%
Mali 666 (498 to 885) 768 (570 to 1047) 15·4% 7318 (6215 to 8660) 5185 (3867 to 7169) –29·2%
Malta 10 (9 to 11) 12 (10 to 13) 17·4% 2781 (2445 to 3159) 2007 (1686 to 2373) –27·8%
Marshall Islands 2 (1 to 2) 2 (2 to 2) 28·2% 5588 (4953 to 6257) 4358 (3764 to 5009) –22·0%
Mauritania 84 (63 to 112) 108 (81 to 140) 28·3% 5274 (4369 to 6368) 3664 (2624 to 4925) –30·5%
Mauritius 34 (31 to 37) 36 (32 to 40) 5·8% 4922 (4593 to 5253) 2738 (2461 to 3056) –44·4%
Mexico 1731 (1495 to 2002) 2414 (2048 to 2838) 39·5% 2772 (2441 to 3145) 2232 (1930 to 2577) –19·5%
Moldova 201 (185 to 218) 165 (150 to 182) –18·0% 5098 (4714 to 5483) 3592 (3263 to 3976) –29·5%
Mongolia 96 (75 to 120) 136 (123 to 151) 40·9% 5738 (5020 to 6651) 6468 (5944 to 7197) 12·7%
Montenegro 28 (26 to 30) 32 (29 to 34) 12·6% 4875 (4486 to 5281) 3933 (3574 to 4319) –19·3%
Morocco 962 (790 to 1143) 970 (796 to 1177) 0·8% 4956 (4362 to 5627) 3407 (2815 to 4100) –31·3%
Mozambique 875 (690 to 1116) 1062 (746 to 1475) 21·4% 6921 (5890 to 8264) 5756 (3711 to 8423) –16·8%
Myanmar 1912 (1439 to 2452) 2010 (1457 to 2662) 5·1% 6857 (4981 to 9046) 4991 (3657 to 6496) –27·2%
Namibia 38 (31 to 44) 52 (38 to 72) 37·2% 4578 (3800 to 5351) 3426 (2455 to 4914) –25·2%
Nepal 1702 (1339 to 2128) 904 (744 to 1066) –46·9% 7684 (6469 to 8998) 3994 (3309 to 4713) –48·0%
Netherlands 476 (423 to 536) 508 (444 to 577) 6·9% 2742 (2418 to 3106) 2131 (1821 to 2484) –22·3%
New Zealand 92 (81 to 103) 108 (94 to 124) 17·4% 2625 (2331 to 2959) 1897 (1620 to 2215) –27·8%
Nicaragua 94 (82 to 106) 109 (92 to 129) 16·7% 3076 (2723 to 3465) 2312 (1980 to 2655) –24·8%
Niger 1259 (801 to 2018) 1267 (883 to 1848) 0·7% 9958 (7256 to 14427) 5869 (4344 to 7786) –41·1%
Nigeria 5744 (4238 to 7818) 5694 (4390 to 7992) –0·9% 5747 (4458 to 7261) 3618 (2864 to 4930) –37·1%
North Korea 703 (558 to 876) 1178 (973 to 1412) 67·7% 4955 (3984 to 6118) 4679 (3888 to 5567) –5·6%
Norway 161 (146 to 178) 141 (124 to 160) –12·3% 2864 (2565 to 3209) 2017 (1723 to 2343) –29·6%
Oman 35 (29 to 43) 71 (57 to 88) 99·7% 3029 (2471 to 3652) 2516 (2140 to 2905) –16·9%
Pakistan 6419 (5315 to 7793) 7283 (6255 to 8567) 13·5% 6131 (5327 to 7083) 5005 (4380 to 5716) –18·4%
Palestine 51 (43 to 61) 96 (80 to 115) 88·6% 4369 (3718 to 5160) 3722 (3109 to 4323) –14·8%
Panama 57 (50 to 65) 86 (73 to 100) 51·0% 3230 (2889 to 3597) 2423 (2080 to 2798) –25·0%
Papua New Guinea 205 (154 to 269) 308 (223 to 438) 49·9% 7826 (5720 to 10186) 6275 (4550 to 8789) –19·8%
Paraguay 109 (97 to 123) 167 (145 to 194) 52·7% 3882 (3513 to 4288) 3298 (2898 to 3786) –15·1%
Peru 610 (533 to 689) 572 (471 to 686) –6·2% 3511 (3123 to 3921) 2066 (1721 to 2442) –41·2%
Philippines 1617 (1439 to 1781) 2883 (2621 to 3173) 78·3% 3885 (3591 to 4190) 3968 (3642 to 4326) 2·1%
Poland 1442 (1315 to 1580) 1351 (1206 to 1503) –6·3% 3743 (3420 to 4100) 2541 (2227 to 2876) –32·1%
Portugal 541 (504 to 581) 401 (357 to 450) –25·8% 4501 (4160 to 4877) 2370 (2052 to 2748) –47·3%
Qatar 9 (7 to 10) 32 (24 to 41) 270·0% 2970 (2543 to 3480) 2220 (1826 to 2683) –25·3%
Romania 1224 (1139 to 1313) 1124 (1044 to 1208) –8·2% 5039 (4687 to 5412) 3817 (3491 to 4175) –24·3%
Russia 8313 (7738 to 8910) 8507 (7857 to 9176) 2·3% 5380 (5009 to 5772) 4220 (3851 to 4600) –21·6%
Rwanda 460 (360 to 585) 378 (288 to 494) –17·9% 8493 (7054 to 10073) 4485 (3236 to 6286) –47·2%
(Table 2 continues on next page)
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All-age DALYs (thousands) Age-standardised rate of DALYs (per 100 000)
1990 2015 Change from 
1990 to 2015*
1990 2015 Change from 
1990 to 2015*
(Continued from previous page)
Saint Lucia 5 (5 to 6) 6 (5 to 7) 10·3% 4773 (4383 to 5192) 3237 (2879 to 3632) –32·2%
St Vincent and the Grenadines 3 (3 to 4) 3 (3 to 4) 0·1% 4181 (3761 to 4616) 3483 (3122 to 3851) –16·7%
Samoa 4 (4 to 5) 4 (3 to 5) –4·0% 4534 (3770 to 5412) 3109 (2547 to 3657) –31·4%
São Tomé and Príncipe 5 (4 to 5) 5 (4 to 8) 19·0% 4788 (4119 to 5510) 4610 (3123 to 6711) –3·7%
Saudi Arabia 317 (263 to 379) 555 (444 to 686) 75·1% 3332 (2859 to 3808) 2705 (2302 to 3158) –18·8%
Senegal 397 (326 to 494) 541 (383 to 748) 36·0% 5637 (4846 to 6563) 5226 (3419 to 7715) –7·3%
Serbia 488 (449 to 529) 476 (440 to 515) –2·5% 5146 (4755 to 5572) 3739 (3408 to 4110) –27·3%
Seychelles 2 (2 to 2) 2 (2 to 3) 9·6% 4015 (3678 to 4382) 2636 (2311 to 3005) –34·4%
Sierra Leone 304 (220 to 453) 308 (228 to 413) 1·3% 6568 (4982 to 8508) 6096 (4473 to 8013) –7·2%
Singapore 61 (54 to 69) 76 (65 to 88) 24·8% 2864 (2613 to 3145) 1612 (1367 to 1896) –43·7%
Slovakia 200 (182 to 220) 176 (156 to 199) –12·0% 3830 (3487 to 4200) 2535 (2225 to 2903) –33·8%
Slovenia 76 (69 to 84) 64 (57 to 73) –15·9% 3553 (3228 to 3903) 2057 (1758 to 2390) –42·1%
Solomon Islands 13 (10 to 17) 21 (14 to 29) 57·3% 7670 (5517 to 10124) 6077 (4252 to 8631) –20·8%
Somalia 603 (401 to 896) 682 (428 to 1121) 13·1% 9690 (5059 to 16652) 7720 (3831 to 14872) –20·3%
South Africa 1110 (1004 to 1226) 1458 (1291 to 1636) 31·4% 4340 (3955 to 4753) 3549 (3176 to 3953) –18·2%
South Korea 1501 (1382 to 1640) 1371 (1216 to 1555) –8·7% 5331 (5028 to 5669) 2185 (1926 to 2496) –59·0%
South Sudan 508 (321 to 771) 691 (423 to 1222) 36·0% 8134 (4561 to 14144) 6548 (3545 to 13257) –19·5%
Spain 1387 (1249 to 1548) 1477 (1276 to 1697) 6·5% 2998 (2671 to 3385) 2006 (1685 to 2378) –33·1%
Sri Lanka 389 (344 to 439) 469 (389 to 566) 20·5% 2748 (2476 to 3062) 2384 (1994 to 2865) –13·3%
Sudan 984 (790 to 1194) 1347 (1095 to 1647) 36·9% 6558 (5444 to 7867) 5257 (4240 to 6467) –19·8%
Suriname 14 (13 to 15) 18 (16 to 20) 30·6% 4520 (4132 to 4920) 3913 (3462 to 4393) –13·4%
Swaziland 23 (18 to 29) 40 (25 to 61) 75·5% 4819 (3679 to 6099) 5399 (3167 to 8410) 12·0%
Sweden 300 (271 to 333) 286 (254 to 326) –4·4% 2458 (2176 to 2803) 1896 (1622 to 2227) –22·9%
Switzerland 222 (197 to 249) 227 (196 to 262) 2·2% 2554 (2236 to 2913) 1875 (1572 to 2224) –26·6%
Syria 472 (398 to 543) 454 (390 to 523) –3·8% 6029 (5346 to 6815) 3733 (3253 to 4249) –38·1%
Taiwan (Province of China) 509 (463 to 559) 533 (461 to 613) 4·8% 3439 (3176 to 3733) 1831 (1590 to 2109) –46·8%
Tajikistan 189 (171 to 208) 237 (207 to 269) 25·1% 5248 (4808 to 5675) 4394 (3942 to 4849) –16·3%
Tanzania 1186 (970 to 1421) 1740 (1290 to 2368) 46·7% 5600 (4737 to 6441) 4364 (3016 to 6521) –22·1%
Thailand 1482 (1332 to 1652) 2033 (1751 to 2339) 37·2% 3723 (3397 to 4099) 2679 (2313 to 3084) –28·0%
The Bahamas 7 (6 to 8) 11 (9 to 12) 48·5% 4025 (3668 to 4457) 2858 (2501 to 3232) –29·0%
The Gambia 40 (31 to 51) 56 (43 to 71) 38·5% 5025 (3647 to 6938) 4166 (3164 to 5411) –17·1%
Timor–Leste 38 (24 to 52) 30 (24 to 38) –19·1% 6251 (4945 to 7614) 3643 (2976 to 4343) –41·7%
Togo 171 (142 to 215) 235 (174 to 308) 37·3% 5474 (4660 to 6395) 4902 (3506 to 6685) –10·4%
Tonga 3 (2 to 3) 3 (2 to 3) 0·3% 3983 (3479 to 4540) 3252 (2775 to 3750) –18·3%
Trinidad and Tobago 40 (36 to 44) 42 (38 to 48) 5·6% 4459 (4103 to 4845) 3114 (2760 to 3496) –30·2%
Tunisia 259 (227 to 294) 317 (265 to 373) 22·5% 4332 (3877 to 4801) 3088 (2577 to 3633) –28·7%
Turkey 2225 (1854 to 2660) 1970 (1693 to 2271) –11·5% 4564 (3926 to 5239) 2778 (2408 to 3176) –39·1%
Turkmenistan 128 (117 to 141) 188 (171 to 207) 46·8% 5312 (4926 to 5798) 4786 (4427 to 5184) –9·9%
Uganda 1254 (962 to 1677) 1558 (1143 to 2088) 24·3% 7413 (5838 to 8909) 5386 (3665 to 7530) –27·3%
Ukraine 2900 (2698 to 3116) 2476 (2267 to 2671) –14·6% 4853 (4494 to 5242) 3676 (3327 to 4045) –24·3%
United Arab Emirates 46 (37 to 57) 212 (168 to 263) 359·0% 4712 (3949 to 5507) 3647 (3072 to 4316) –22·6%
UK 2274 (2057 to 2522) 2018 (1777 to 2307) –11·3% 3065 (2722 to 3466) 2207 (1875 to 2600) –28·0%
England 1865 (1686 to 2070) 1651 (1453 to 1886) –11·5% 3001 (2668 to 3390) 2149 (1825 to 2530) –28·4%
Northern Ireland 55 (49 to 61) 55 (48 to 63) 0·8% 3025 (2675 to 3415) 2261 (1933 to 2631) –25·3%
Scotland 235 (210 to 263) 203 (177 to 235) –13·3% 3679 (3236 to 4186) 2708 (2270 to 3232) –26·4%
Wales 120 (109 to 132) 109 (96 to 123) –8·9% 3081 (2746 to 3452) 2297 (1977 to 2690) –25·4%
USA 6812 (6031 to 7722) 8776 (7741 to 9939) 28·8% 2447 (2154 to 2790) 2109 (1831 to 2432) –13·8%
Uruguay 116 (106 to 127) 110 (99 to 122) –4·8% 3503 (3196 to 3849) 2509 (2232 to 2840) –28·4%
Uzbekistan 680 (609 to 750) 919 (817 to 1028) 35·1% 5064 (4627 to 5483) 4126 (3747 to 4541) –18·5%
(Table 2 continues on next page)
Articles
890 www.thelancet.com/neurology   Vol 16   November 2017
southern sub-Saharan Africa, and a modest decrease 
elsewhere. The small increase in the global age-
standardised prevalence of Alzheimer’s disease and 
other dementias is in contrast with a significant 
reduction from 1990 to 2015 in the prevalence of stroke, 
despite stroke sharing risks with, and contributing to, 
vascular dementia. For stroke, blood pressure control 
and smoking cessation have been important 
contributors to the reduction of its incidence in high-
income and middle-income countries.27–29 Diverging 
trends of stroke and dementia incidence rates have been 
reported elsewhere.30 However, the most striking change 
has been the more than doubling of people in the world 
who die or are disabled from Alzheimer’s disease and 
other dementias over the past 25 years. As ageing of the 
global population continues, our findings have 
important major health-service implications for the care 
of patients and adequate support for affected families.
Vaccinations have contributed to the favourable trends 
in the DALY rates of tetanus, meningitis, and 
encephalitis.31–37 Our estimate of 23·4 million cases of 
active epilepsy in 2015 is lower than the 32·7 million 
cases estimated in a meta-analysis of 65 prevalence 
studies, although that study did not specify a year of 
estimate.38 Similar to findings from this meta-analysis, 
we noted large geographical variations in the prevalence 
of epilepsy, with significantly greater rates in low-income 
and middle-income countries. The high prevalence of 
epilepsy in low-income and middle-income countries 
can partly be accounted for by the greater number of 
cases with communicable causes in these countries.38,39 
Our 2015 prevalence estimates are within the ranges 
reported for Parkinson’s disease (51–177 per 100 000 
people),40 motor neuron disease (1·9–3·9 per 100 000 
people),41,42 tension-type headache (21–27%),43,44 
medication overuse headache (0·5%–7·2%),45 and 
migraine (mean estimate 10%, range 1–25),46 but lower 
than that reported for multiple sclerosis (65–74 per 
100 000 people),47 dementias (4·2–8·0% in people aged 
60 years or older),48 and stroke (0·4–2·1% in low-income 
and middle-income countries).49 Differences in study 
populations (eg, age range and countries included) might 
account for some of the observed differences in 
prevalence rates.
Between countries, age-standardised rates of DALYs 
and deaths from neurological disorders as a group varied 
up to six times, with the highest rates in low-income to 
middle-income countries. These geographical patterns of 
the burden and distribution of individual neurological 
disorders are important for global and regional health-
care planning and might inform further research to 
examine possible causes of the diseases. For example, 
the clear latitudinal gradient we noted in the prevalence 
of multiple sclerosis (about two times higher prevalence 
in countries at highest latitudes compared with those on 
the equator) corresponds to that observed in other 
studies50,51 and is suggestive of the role of environmental 
factors (eg, vitamin D deficiency and infection).52,53
Our findings of large geographical variations in the 
burden of stroke, dementias, Parkinson’s disease, 
epilepsy, migraine, medication overuse headache, motor 
neuron disease, and brain and nervous system cancers 
concur with previous observations.17,24,26,38,45,46,48,54–58 In non-
communicable neurological disorders, the largest (greater 
than 20 times) variations in age-standardised DALYs were 
observed for stroke, motor neuron disease, and multiple 
sclerosis; in communicable neurological disorders, 
geographical differences ranged from 100 times for 
encephalitis to 10 000 times for tetanus. The greater 
geographical variation of communicable disorders was 
related to their overwhelming predominance in countries 
at low levels of socio-demographic development and 
emphasised the need for better prevention (including 
vaccination and sanitation measures), as well as better 
case management in these regions.
We noted significant sex differences in the burden of 
many neurological disorders analysed (higher prevalence 
of tetanus, stroke, Parkinson’s disease, and motor neuron 
disease, but lower prevalence of multiple sclerosis and 
various types of headaches in males). The greater 
prevalence of stroke,59 Parkinson’s disease,24 epilepsy,60 
and motor neuron disease61 in males has also been 
All-age DALYs (thousands) Age-standardised rate of DALYs (per 100 000)
1990 2015 Change from 
1990 to 2015*
1990 2015 Change from 
1990 to 2015*
(Continued from previous page)
Vanuatu 6 (5 to 8) 10 (7 to 14) 64·7% 7084 (5199 to 9626) 5797 (4304 to 7946) –18·2%
Venezuela 435 (382 to 498) 649 (551 to 755) 49·2% 3378 (3051 to 3753) 2556 (2208 to 2935) –24·3%
Vietnam 2310 (1974 to 2691) 3179 (2588 to 3745) 37·6% 4775 (4164 to 5511) 3862 (3134 to 4523) –19·1%
Yemen 615 (436 to 791) 851 (629 to 1175) 38·3% 6756 (4862 to 9201) 5734 (4079 to 8182) –15·1%
Zambia 557 (425 to 738) 636 (493 to 823) 14·3% 6691 (5443 to 7948) 5755 (4199 to 7711) –14·0%
Zimbabwe 282 (237 to 336) 451 (339 to 595) 60·0% 3629 (2993 to 4329) 4009 (2809 to 5567) 10·5%
Data are n or % with 95% uncertainty intervals (UI). For more details on disorder, country, year, age, and sex, see the Global Burden of Disase compare website https://vizhub.healthdata.org/gbd-compare/. 
DALYs=disability-adjusted life-years. *UIs cannot be calculated for aggregated estimates of percentage changes.
Table 2: Global absolute number of DALYs and age-standardised rates per 100 000 people for all neurological disorders combined and percentage changes between 1990 and 2015 by country
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reported by other studies. A greater prevalence in females 
has been reported elsewhere for migraine62 and multiple 
sclerosis.50 Our finding of 22% higher age-standardised 
prevalence of Alzheimer’s disease and other dementias 
in women is in accordance with a finding from a meta-
analysis of consistently higher estimates among 
160 studies, although it was reported not to be 
significant.48 The higher age-standardised rate might be 
partly due to having a top age category of 80 years and 
older. As dementia is so highly prevalent at oldest ages, 
greater age detail in estimation of dementia prevalence 
might reduce the observed sex difference.
Our study findings have important health service 
implications. The large and increasing numbers of 
patients with neurological disorders necessitate careful 
planning by governments and other health-care providers 
to ensure adequate funding and staff for their treatment 
and rehabilitation services. However, a recent WHO–
World Federation of Neurology survey63 of services and 
other resources for neurological disorders in 
109 countries (90% of the world population) showed that 
there are large inequalities in access to neurological care 
across different populations, in particular for those living 
in low-income to middle-income countries. With a 
global shortage of neurologists, neuro surgeons, and 
rehabilitation professionals, improving neurological care 
will require innovative strategies within existing health 
systems. A good example of such innovative strategies is 
the use of nurses, nurse practitioners, and physician 
assistants trained in stroke care to care for patients with 
acute stroke and transient ischaemic attack in stroke 
units. A recently suggested implementation cycle for 
combating cardiovascular disease in low-income to 
middle-income countries64 provides a good template for 
similar interventional strategies for reducing the burden 
of neuro logical disorders in such countries. Although 
improving care and rehabilitation of people with 
neurological disorders is important for improving 
outcomes, there also are effective primary prevention 
strategies for communicable neurological disorders and 
stroke. However, proven effective preventive strategies 
are often underutilised.65,66 More quality epidemiological 
research on risk factors, incidence, prevalence, and 
outcomes of neurological disorders in various countries 
is required to guide better prevention and management 
of these disorders, and our findings could help to 
prioritise such efforts. The sex, age, and regional and 
national differences and trends in the burden of 
neurological disorders necessitate the development, 
implementation, and prioritisation of treatments and 
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Figure 5: Expected relationship between the Socio-demographic Index and 
DALY rates for neurological disorders per 100 000 people between 
1990 and 2015
Age-standardised disability-adjusted life-years (DALYs) per 100 000 people (A) 
by sex; (B) all-age DALY rate per 100 000 by sex; and (C) age-standardised rate 
per 100 000 by years of life lost (YLLs) and years lived with disability (YLDs).
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preventive interventions that are specific for sex, age, and 
population to reduce the burden from these disorders.
Although ours was the most up-to-date overview of the 
global burden of major neurological disorders, this study 
was not free from some limitations in addition to overall 
GBD limitations.3,4 First, we assumed that the excess 
mortality in Alzheimer’s disease and other dementias 
implied by prevalence and mortality rates in countries 
that were most willing to code deaths to dementia in 
their vital registrations would apply to all other countries 
and periods. Although we realised that excess mortality 
was unlikely to be generalisable over location and time, 
we chose to make this assumption to address the much 
larger change we observed in deaths certified as 
Alzheimer’s disease and other dementias between 
countries and over time than seen in prevalence or 
incidence studies. Second, estimates of cause-specific 
death rates in most low-income and middle-income 
countries rely on verbal autopsy data rather than 
physician-certified death records. Verbal autopsy 
instruments can identify deaths due to some neurological 
disorders, including stroke, meningitis, tetanus, and 
epilepsy, but are unable to capture other neurological 
disorders.67 Third, there are also many gaps in data 
availability by world region, and many low-income and 
middle-income regions do not have any epidemiological 
data. Epilepsy is the only neurological disorder with data 
sources for all 21 GBD regions. Fourth, heterogeneity in 
study methods and case definitions complicates the non-
fatal estimation. Although we endeavoured to adjust for 
such methodological differences, this relied on 
generalising adjustment factors from few studies. Fifth, 
some categories of neurological disease were not 
included in this analysis because of an inability to 
aggregate cause-level and sequela-level data. For this 
reason, we were unable to include secondary epilepsy, 
the long-term neurological consequences of neonatal 
disorders, or traumatic brain injury and spinal cord 
injury, which are estimated in GBD as sequelae of 
injuries such as falls or road injuries. Adding currently 
missed neurological disorders would increase the health 
significance of the neurological disorders for public 
health systems and should be possible in a future GBD 
iteration. Sixth, sparse data on the severity of these 
neurological diseases did not allow us to differentiate 
severity by location or over time, with the exception of 
epilepsy (appendix pp 5–113). Relying on few studies, 
often from high-income countries only, meant we were 
unable to quantify any treatment effects on severity.
In conclusion, we have shown that neurological 
disorders are a large cause of disability and death 
worldwide. Globally, the burden of neurological disorders 
has increased substantially over the past 25 years because 
of population ageing, despite substantial decreases in 
mortality rates from stroke and communicable 
neurological disorders. Because low-income and middle-
income countries still have a long way to go through the 
demographic transition of reductions in child mortality 
and population ageing, the number of patients who will 
need neurological care will continue to grow in the 
coming decades. It is important that policy makers and 
health-care providers are aware of these past trends to be 
able to provide adequate services for the growing 
numbers of patients with neurological disorders.
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